|
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
FGF21 is a promising intervention therapy for metabolic diseases as fatty liver, obesity and diabetes.
|
23590285 |
2013 |
|
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In NASH mice, administration of PsTag600-FGF21 reduced hepatic steatosis, fibrosis and inflammation.
|
29870802 |
2018 |
|
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study assessed pegbelfermin (BMS-986036), recombinant PEGylated human fibroblast growth factor 21 (FGF21), in patients with obesity and T2DM predisposed to fatty liver.
|
30520566 |
2019 |
|
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
ACC DKI mice had improved glucose and insulin tolerance and a reduction in body weight, body fat and hepatic steatosis similar to WT mice in response to FGF21 administration.
|
28580278 |
2017 |
|
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
FGF21 depletion exacerbated alcohol-induced hepatic steatosis and liver injury, which was associated with increased activation of genes involved in lipogenesis mediated by SREBP1c and decreased expression of genes involved in fatty acid β-oxidation mediated by PGC1α. rhFGF21 administration reduced alcohol-induced hepatic steatosis and inflammation in WT mice.
|
27498701 |
2016 |
|
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Equally, repressed expression of the B-lymphocyte chemoattractant CXCL13 and STAT4 as well as induced FGF21 evidenced amelioration of steatosis-related inflammation.
|
27376874 |
2016 |
|
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Liver X receptor negatively regulates fibroblast growth factor 21 in the fatty liver induced by cholesterol-enriched diet.
|
21889884 |
2012 |
|
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Fatty liver and FGF21 physiology.
|
28549912 |
2017 |
|
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Administration of recombinant FGF21 in mice alleviated tunicamycin-induced liver steatosis, in parallel with reduced eIF2α-ATF4-CHOP signaling.
|
25170079 |
2014 |
|
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, by using a neutralizing antibody against FGF21, Fgf21-null mice and by treating mice with recombinant FGF21, we show that FGF21 may protect against hepatic steatosis by attenuating endoplasmic reticulum (ER) stress-induced VLDLR upregulation.
|
29289645 |
2018 |
|
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Constitutive ISR activation in the liver induces FGF21 and confers protection from HFD-induced adiposity, IR, and HS in mice.
|
29698569 |
2018 |
|
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The significant positive correlation of FGF-21 with ALT, gamma glutamyltransferase (GGT), triglycerides, homeostatic model assessment-insulin resistance (HOMA-IR), the degree of liver steatosis in ultrasound and TILC in <sup>1</sup>H-MRS were found.
|
30921653 |
2019 |
|
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study aimed to evaluate FGF-21 as a biomarker for severe hepatic steatosis in non-obese HIV-infected patients.
|
30916873 |
2019 |
|
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
APS treatment suppressed abnormal glycolipid metabolism and insulin resistance following 8 weeks of catch‑up growth by improving hepatic SIRT1‑PPARα‑FGF21 intracellular signaling and reducing chronic inflammation, and by partially attenuating hepatic steatosis.
|
26323321 |
2015 |
|
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
This corresponds to an induction of FGF21, which is required for long-term steatosis protection, as FGF21KO mice are refractory to the improved metabolic effects.
|
29290411 |
2018 |
|
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Berberine attenuated hepatic steatosis and controlled energy balance in mice by inducing autophagy and FGF21.
|
29065221 |
2018 |
|
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
FGF21-based drugs induce weight loss and improve dyslipidemia in patients with obesity and T2D, and reduce steatosis in patients with NASH.
|
30893110 |
2019 |
|
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Concentration of FGF-21 was greater in fatty liver cows, while the concentration of LP-PLA2 and Hb was less.
|
30206404 |
2018 |
|
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results suggest that FGF21 can be used for early identification of hepatic steatosis.
|
28698650 |
2017 |
|
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
FGF21 KO mice were subjected to chronic-binge alcohol exposure, and epididymal white adipose tissue lipolysis and liver steatosis were investigated.
|
26092866 |
2015 |
|
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The administration of FGF21 reverses hepatic steatosis, counteracts obesity and alleviates insulin resistance in rodents and nonhuman primates.
|
25516477 |
2015 |
|
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
To determine if higher plasma FGF21 is associated with worse steatohepatitis on liver biopsy in patients with nonalcoholic fatty liver disease (NAFLD).
|
30848827 |
2019 |
|
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we show that chronic PD retards the development of hypertrigylceridemia and fatty liver in obesity and that this relies on the induction of the hepatokine fibroblast growth factor 21 (FGF21).
|
29751292 |
2018 |
|
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
A Novel Role of SIRT1/ FGF-21 in Taurine Protection Against Cafeteria Diet-Induced Steatohepatitis in Rats.
|
28942443 |
2017 |
|
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Fibroblast growth factor 21 is required for the therapeutic effects of Lactobacillus rhamnosus GG against fructose-induced fatty liver in mice.
|
31668386 |
2019 |